Peng Lu - 18 Mar 2026 Form 3 Insider Report for Pharvaris N.V. (PHVS)

Role
Chief Medical Officer
Signature
/s/ Marnus Nel, Attorney-in-Fact for Peng Lu
Issuer symbol
PHVS
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 14:23:19 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lu Peng Chief Medical Officer 1 CRANBERRY HILL SUITE 400, LEXINGTON /s/ Marnus Nel, Attorney-in-Fact for Peng Lu 18 Mar 2026 0001972159

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PHVS Common Stock 66,309 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PHVS Stock Option (Right to Buy) 18 Mar 2026 Common Stock 70,000 $28.00 Direct F2
holding PHVS Stock Option (Right to Buy) 18 Mar 2026 Common Stock 67,500 $16.05 Direct F3
holding PHVS Stock Option (Right to Buy) 18 Mar 2026 Common Stock 65,000 $22.31 Direct F4
holding PHVS Stock Option (Right to Buy) 18 Mar 2026 Common Stock 73,118 $8.05 Direct F5
holding PHVS Stock Option (Right to Buy) 18 Mar 2026 Common Stock 6,882 $8.05 Direct F6
holding PHVS Stock Option (Right to Buy) 18 Mar 2026 Common Stock 57,669 $18.14 Direct F7
holding PHVS Stock Option (Right to Buy) 18 Mar 2026 Common Stock 7,301 $18.14 Direct F8
holding PHVS Stock Option (Right to Buy) 18 Mar 2026 Common Stock 14,000 $20.00 Direct F9
holding PHVS Stock Option (Right to Buy) 18 Mar 2026 Common Stock 65,000 $20.00 Direct F9
holding PHVS Stock Option (Right to Buy) 18 Mar 2026 Common Stock 245,308 $2.59 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: - 25,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -17,250 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -11,120 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter.
F2 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.
F3 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.
F4 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.
F5 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
F6 25% of the option vested on January 6, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.
F7 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
F8 25% of the option vested on January 1, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.
F9 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.
F10 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.